In the 117-person INSPIRE trial, researchers report the prebiotic cut pain and lifted the body's own GLP-1, which tracked with better grip strength.
Recap by typeshit. Full story at Science Daily.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
The ruling only covers interim relief, so Novo's lawsuit over the comparative ads continues. The company reports nine-month results on November 4.
Lilly reports average losses of 19.5% to 20.9% at 80 weeks versus 9.4% on Ozempic 2 mg, with A1C down 2.2% against 1.8%. Dropouts from side effects ran higher on retatrutide.
Loading…